ArticleMolecular biology reports2026
Voriconazole treated human monocyte derived dendritic cells exhibit modulatory features with augmented surface expression of maturation and stimulatory markers.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDendritic cells (DCs) regulate the balance between immune activation and tolerance. Given the immunomodulatory properties of voriconazole, this study investigated its effects on the maturation, activation, and inflammatory profile of human monocyte-derived DCs. METHODS AND
resultsPBMCs were isolated from healthy human blood donors using Ficoll density gradient centrifugation. Monocytes were isolated via plastic adherence and then differentiated into monocyte-derived dendritic cells (moDCs). The cells were treated with voriconazole and LPS, or with LPS alone. The expression levels of CD11c, CD14, HLA-DR, and CD86 on dendritic cells (DCs) were evaluated by flow cytometry. The mRNA levels of genes and cytokines involved in DC maturation and function were quantified by qRT-PCR and ELISA. The research demonstrated that voriconazole-treated dendritic cells expressed higher levels of CD11c (p ≤ 0.001), HLA-DR (p ≤ 0.0001), and CD86 (p ≤ 0.0001), which are markers of maturation and antigen presentation, respectively. Voriconazole suppressed the expression of both anti-inflammatory and inflammatory genes, such as IL-10 (p ≤ 0.0001), IDO (p ≤ 0.0001), IL-18 (p ≤ 0.0001), and TNF-α (p ≤ 0.0001), in dendritic cells. Significant decreases in the concentrations of IL-1β (p ≤ 0.0001) and TNF-α (p ≤ 0.001) cytokines were observed according to ELISA data, although IL-12 levels did not change appreciably (not significant).
conclusionVoriconazole increased the expression of dendritic cell maturation markers, enhancing the maturation process and readiness for antigen presentation. In addition, voriconazole reduced the expression of inflammatory and anti-inflammatory genes. The corresponding decrease in protein levels further indicated balanced immune regulation. These findings highlight the immunomodulatory potential of voriconazole and warrant further investigation.
Indexed as
Identifiers
42467284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.